Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zotatifin And EIF4A Platinum Helix Inhibition In Resistant AdvancedTNBC

NCT07783659 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT07783659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07783659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zotatifin And EIF4A Platinum Helix Inhibition In Resistant AdvancedTNBC
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
February 12, 2027
Completion date
June 30, 2032
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced tnbc, eif4a, phase ib, platinum helix inhibition, zotatifin